203 filings
Page 4 of 11
8-K
lg0apzs3yhe
20 May 22
Evofem Biosciences Announces Proposed Public Offering
7:55pm
8-K
lz004cav73r4a734
20 May 22
Termination of a Material Definitive Agreement
6:01am
8-K
695a7mu8 xjq
12 May 22
Regulation FD Disclosure
8:01am
8-K
4ak2irpvmgwrh
5 May 22
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
9:03am
8-K
hu60kdog
4 May 22
Evofem Biosciences Reports First Quarter 2022
4:05pm
8-K
hdzxb1
7 Apr 22
Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of
6:51am
8-K
qj3ysdm7
6 Apr 22
Entry into a Material Definitive Agreement
7:36pm
8-K
d2co9dxqdvp9x iuqz
24 Mar 22
Entry into a Material Definitive Agreement
4:03pm
8-K
7skfz
21 Mar 22
Entry into a Material Definitive Agreement
4:35pm
8-K
2a8vk4l41c0 6oej78
3 Mar 22
Evofem Biosciences Reports Fourth Quarter and Year-End 2021
4:11pm
8-K
91rz9i7o2o570j1pfr
1 Mar 22
Entry into a Material Definitive Agreement
10:53am
8-K
rnm0vt0e az
28 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K/A
n778q6n0
16 Feb 22
Entry into a Material Definitive Agreement
4:05pm
8-K
cvsy6p
16 Feb 22
Entry into a Material Definitive Agreement
6:22am
8-K
qnzmgvi iqkas7r8f5t
15 Feb 22
Regulation FD Disclosure
4:10pm
8-K
wt76hq wstno7lwf
19 Jan 22
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
9:01am
8-K
boblnw
13 Jan 22
Entry into a Material Definitive Agreement
8:43am
8-K
o6z2v9d
15 Dec 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
xnwk ngyitf
9 Dec 21
Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
8:00am
8-K
ymb89d
8 Dec 21
Other Events
6:30am